USFDAJul 7, 2026, 12:56 PM
Vera Therapeutics' TRUTAKNA gets FDA accelerated approval
AI Summary
Vera Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for TRUTAKNA™ (atacicept-vymj). This approval is specifically for reducing proteinuria in adult patients diagnosed with primary immunoglobulin A nephropathy who are at risk for disease progression.
Key Highlights
- Vera Therapeutics' TRUTAKNA™ (atacicept-vymj) received accelerated approval from the U.S. FDA.
- The approval is for reducing proteinuria in adults with primary immunoglobulin A nephropathy.
- The drug targets patients at risk for disease progression.
Price Impact
More from VERA